None listed
Conditions
Brief summary
The purpose of this study is to determine if larger doses of radiation given over a shorter period of time, as compared to standard radiation therapy, given with chemotherapy and followed by immunotherapy is safe for participants. Who is it for? You may be eligible for this study if you are an adult with non-small cell lung cancer. Study details All participants will receive radiation daily with chemotherapy weekly for 4 weeks. They will then receive immunotherapy either fortnightly or monthly for up to 12 months. It is hoped that this study will then determine if further research into this treatment method is necessary.
Interventions
All participants will receive radiotherapy with chemotherapy followed by maintenance immunotherapy.
Radiotherapy will be delivered to a total dose of 55 Gray (Gy) in 20 fractions at 2.75 Gy per fraction daily, 5 days per week over 4 weeks.
Chemotherapy will be delivered intravenously weekly for 4 weeks consisting of Paclitaxel (45mg/m2) and carboplatin (2AUC). Other platinum doublets allowable at the discretion of medical oncologists after discussion with Principal Investigator.
Maintenance im
All participants will receive radiotherapy with chemotherapy followed by maintenance immunotherapy. Radiotherapy will be delivered to a total dose of 55 Gray (Gy) in 20 fractions at 2.75 Gy per fraction daily, 5 days per week over 4 weeks. Chemotherapy will be delivered intravenously weekly for 4 weeks consisting of Paclitaxel (45mg/m2) and carboplatin (2AUC). Other platinum doublets allowable at the discretion of medical oncologists after discussion with Principal Investigator. Maintenance immunotherapy consists of Durvalumab either 10mg/kg in 26 x 14-day cycles or 1500mg in 13 x 28-day cycles to the maximum number of cycles or until disease progression or unacceptable toxicity. Treatment details will be captured within the electronic case record forms.
Sponsors
Calvary Mater Newcastle
Study design
Allocation
Non-randomised trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Unresectable locally advanced Non-small cell lung carcinoma Considered suitable to receive chemoradiation and immunotherapy ECOG performance status 0-2
Exclusion criteria
Unable to meet radiotherapy planning constraints Previous thoracic radiotherapy Life expectancy less than 3 years Received induction chemotherapy prior to chemoradiotherapy
Outcome results
None listed